Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes

Philip F. Halloran1,2 | Katelynn S. Madill-Thomsen1 | Shane Pon1 | Majid L. N. Sikosana1 | Georg A. Böhmig3 | Jonathan Bromberg4 | Gunilla Einecke5 | Farsad Eskandary3 | Gaurav Gupta6 | Luis G. Hidalgo7 | Marek Myslak8 | Ondrej Viklicky9 | Agnieszka Perkowska-Ptasinska10 | the INTERCOMEX Investigators#

1Alberta Transplant Applied Genomics Centre, Edmonton, Alberta, Canada
2Department of Medicine, Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, Alberta, Canada
3Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
4University of Maryland, Baltimore, Maryland, USA
5Department of Nephrology, Hannover Medical School, Hannover, Germany
6Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA
7University of Wisconsin, Madison, Wisconsin, USA
8Department of Clinical Interventions, Department of Nephrology and Kidney Transplantation SPWSZ Hospital, Pomeranian Medical University, Szczecin, Poland
9Department of Nephrology and Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
10Department of Pathology, Medical University of Warsaw, Warsaw, Poland

Correspondence
Katelynn S. Madill-Thomsen, PhD, Alberta Transplant Applied Genomics Centre, #250 Heritage Medical Research Centre, University of Alberta, Edmonton, AB, Canada.
Email: kmadill@ualberta.ca

Funding information
Dr. Halloran held a Canada Research Chair in Transplant Immunology until 2008 and currently holds the Muttart Chair in Clinical Immunology. This research has been principally supported by grants from Genome Canada, Canada Foundation for Innovation, the University of Alberta Hospital Foundation, the Alberta Ministry of Health and Services.

We studied the clinical, histologic, and molecular features distinguishing DSA-negative from DSA-positive molecularly defined antibody-mediated rejection (mABMR). We analyzed mABMR biopsies with available DSA assessments from the INTERCOMEX study: 148 DSA-negative versus 248 DSA-positive, compared with 864 no rejection (excluding TCMR and Mixed). DSA-positivity varied with mABMR stage: early-stage (EABMR) 56%; fully developed (FABMR) 70%; and late-stage (LABMR) 58%. DSA-negative patients with mABMR were more often C4d-negative; earlier by 1.5 years (average 2.4 vs. 3.9 years); and had lower ABMR activity and earlier stage in molecular and histology features. However, the...
of Advanced Education and Technology, the Mendez National Institute of Transplantation Foundation, and Industrial Research Assistance Program. Partial support was also provided by funding from a licensing agreement with the One Lambda division of Thermo Fisher; Mendez National Institute of Transplantation Foundation; Ministry of Advanced Education and Technology; University of Alberta; Canada Foundation for Innovation; Genome Canada.

**1 | INTRODUCTION**

In kidney transplant biopsies, antibody-mediated rejection (ABMR) is characterized by a constellation of molecular features, histologic microcirculation changes, donor-specific human leukocyte antigen (HLA) antibody (DSA), and complement factor d (C4d) deposition.\(^1\)\(^-\)\(^10\) Recently, considerable attention has focused on ABMR lacking detectable circulating DSA. When we defined ABMR molecularly (mABMR), we found that mABMR was often DSA-negative, although usually HLA antibody (“PRA”)-positive\(^11\): even fully developed mABMR (FABMR) was only 76% DSA positive.\(^12\) Senev et al.\(^13\) showed that 85 DSA-positive ABMR and 123 DSA-negative ABMR were histologically similar, but DSA-negative ABMR was more often C4d-negative, more transient, and had superior graft survival. Callemeyn et al.\(^14\) found that 26 kidney allografts with histologic microvascular inflammation (MVI), but no DSA had typical ABMR-induced transcript changes. Natural killer (NK) cell recognition of missing-self may be involved in DSA-negative ABMR, but DSA eluted from kidney biopsies is similar to circulating DSA rather than displaying unique specificities.\(^15\)\(^9\) A possible role for autoantibodies such as anti-AT1R has been raised,\(^20\)\(^21\) potentially interacting with alloantibody mechanisms.\(^22\)\(^23\)

Although many previous reports have focused on histologically defined DSA-negative ABMR, the present study sought to define the clinical, histologic, and molecular features of DSA-negative ABMR when ABMR is defined exclusively by automatically assigned molecular archetype classes using the Molecular Microscope algorithms. This allows us to study the clinical and histologic features of DSA without using those features for diagnosis. In the present study, we used biopsies collected in the INTERCOMEX study (ClinicalTrials.gov NCT01299168) classified by molecular archetypes to study how histology lesions, DSA details, C4d, and outcomes distribute in DSA-negative versus DSA-positive mABMR. Acknowledging that histologic DSA-negative and DSA-positive ABMR are transcriptionally similar,\(^14\) we focused on genome-wide comparisons to discover transcripts that might reveal distinct mechanisms operating in DSA-negative mABMR.

**2 | MATERIALS AND METHODS**

**2.1 | Population and demographics**

All 1679 biopsies were prospectively collected at participating international centers collaborating on the INTERCOMEX study (Table S1) as previously described.\(^24\)\(^25\) Biopsy and patient demographics of the full population are shown in Table S1. Table S1 shows a list of abbreviations. Selected transcript sets are described in Table S1. Table S1 shows histology and Molecular Microscope Diagnostic System (MMDx) diagnoses along with DSA status. DSA status was defined as the standard-of-care (SOC) diagnosis by the local HLA laboratory, as required by the Banff guidelines (see Discussion). When patients had more than one indication biopsy, all were included because we found that there was no effect of exclusion of repeat biopsies.

The research plan is summarized in Figure 1.

**2.2 | Selection of biopsies with recorded donor-specific HLA antibody status**

We studied the biopsies in the 1679 cohort with recorded DSA status per SOC at the local center. In DSA-positive versus DSA-negative
comparisons, only mABMR biopsies with available status were used (N = 398). As a baseline, we used biopsies called No rejection by molecular archetypes with available DSA status (N = 854).

2.3 | Archetypal analysis

Archetypal analysis is an unsupervised method that generates clusters based on the multidimensional distribution of input variables. The dominant input features define the “archetype” locations—hypothetical samples representing extreme phenotypes within the distribution. As published,12,26 rejection archetypes used g > 1_Prob, ptc > 1_Prob, cg > 0_Prob, ABMR_Prob, TCMR_Prob, i > 1_Prob, and t > 1_Prob, classifier scores as input. These represent molecular estimates of histologic rejection and the key lesion scores used in those diagnoses.

The number of clusters is user-chosen, guided by the trade-off between complexity (more clusters) and model quality, visualized as a scree plot (not shown). Based on this, and the biological interpretability of the clusters, six archetypes were chosen. Their names were based on their average histologic and molecular characteristics: no rejection, TCMR1 (often mixed and associated with nonadherence), TCMR2, early-stage ABMR (EABMR), FABMR, and late-stage ABMR (LABMR). Each biopsy gets a score from 0.0 to 1.0 for each archetype, summing to 1.0. Scores are interpreted as the proportional contribution of each of the six archetypes. A biopsy’s “cluster” was defined as the highest of its six archetype scores.

Biopsies in any of EABMR, FABMR, or LABMR were defined as “mABMR.” Because the archetypes were assigned independent of their DSA or C4d status, an examination of the mABMR relationships with variables such as DSA and C4d was possible.

For the present study, we have emphasized the archetypal clustering because it is completely automatic and avoids subjectivity. However, the biopsies are always signed out in MMDx based on both the archetypal scores and the binary classifiers provided on the MMDx report. This is because archetypes are proportions and therefore can be misleading when more than one score is elevated.

2.4 | Moving average plots

Moving averages (window size 150) were plotted by first sorting the biopsies by their time posttransplant, then plotting the mean of biopsies 1–150 y-variable values against the mean of the biopsies 1–150 days posttransplant. The window is then slid to biopsies 2–151, 3–152, etc. with the process repeated and the mean score plotted each time. This method was selected to permit comparisons with past analyses.12

2.5 | Statistical analysis

All analyses used version 4.1.0 of R.27 We performed t-tests, Chi-squared analyses, and Fisher’s exact test when comparing different histologic and DSA groups within the ABMR archetype population. Differential gene expression was done using a Bayesian t-test from R’s “limma” package.28
3 | RESULTS

3.1 | Rederiving the archetype classes

The archetype classifications developed in the first 1208 biopsies were completely rederived in 1679 biopsies using the same strategies. As in previous analyses, biopsy groups were assigned automatically based on highest archetype score. This established the following rejection classes, similar to earlier analysis: 1040 No rejection, 175 TCMR (including mixed: 75 TCMR1 and 100 TCMR2), and 464 mABMR (210 EABMR, 182 FABMR, and 72 LABMR). The TCMR/mixed biopsies will not be discussed in this paper and will be presented in detail in a separate analysis (in preparation).

We analyzed the features of all 464 mABMR biopsies (regardless of DSA status) in terms of diagnoses, lesions, transcript sets, and genes (Table 1), including 1040 No rejection for comparison. Within mABMR, there was a progression in mean time of biopsy posttransplant: EABMR 2.1 years; FABMR 4.1 years; LABMR 7.6 years. The mean eGFR (cc/min/M²) declined from 50 in EABMR to 43 in FABMR and 32 in LABMR. The histology ptc- and g- scores and v- lesions, and the arterial fibrous intimal thickening (cv-score) scores, were highest in FABMR. The cg- and hyalinosis scores were highest in LABMR.

(The use of automated archetype assignments means that some biopsies will have ambiguous features e.g. biopsies with ABMR-like features below the diagnostic thresholds, i.e., boundary discrepancies. Twelve of 1040 NR biopsies by archetype assignment had positive scores [above the threshold] for the binary ABMR and Rejection classifiers and eight were signed out as ABMR by MMDx on the report. Of 83 biopsies called NR by archetype assignment but called ABMR by histology, 52 were DSA-positive, 33 were C4d-positive; 22 had an ABMR<sub>prob</sub> classifier score above the threshold [0.20]; 23 were signed out as MMDx ABMR; and 17 failed.)

3.2 | Relationships between time posttransplant and the findings within the 464 mABMR biopsies

Figure 2A shows that within mABMR, the ABMR<sub>prob</sub> molecular classifier score rose then plateaued after 500 days. Other ABMR activity classifier scores (ptc<sub>prob</sub>, and g<sub>prob</sub>) rose slightly in the first 500 days but were high throughout the posttransplant period. The cg<sub>prob</sub> classifier was low initially and rose steadily over time. Among archetype scores (Figure 2B), EABMR scores were high early and declined steadily as the FABMR score increased, with the LABMR score increasing after 500 days.

In Figure 2C, the mean histologic ptc- and g- scores in mABMR were high throughout the posttransplant period. The histologic

| TABLE 1 | Clinical variables and histologic lesion scores in the No rejection and mABMR archetype clusters |
|---|---|
| Variable | Mean value or score in each archetype<sup>a</sup> |
| | No rejection (N = 1040) | All mABMR (N = 464) | EABMR (N = 210) | FABMR (N = 182) | LABMR (N = 72) |
| **Clinical** | | | | | |
| Median time of biopsy posttransplant (days) | 371 | 1159 | 724 | 1482 | 2744 |
| GFR (cc/min) | 44 | 45 | 50 | 43 | 32 |
| Proteinuria<sup>b</sup> | 0.55 | 0.69 | 0.58 | 0.78 | 0.77 |
| Donor age (years) | 46 | 42 | 46 | 38 | 39 |
| Recipient age (years) | 52 | 49 | 51 | 47 | 47 |
| **ABMR lesions** | | | | | |
| g (glomerulitis) | 0.27 | 1.28 | 1.07 | 1.70 | 0.87 |
| ptc (capillaritis) | 0.25 | 1.35 | 1.08 | 1.81 | 1.03 |
| cg (double contours) | 0.18 | 0.99 | 0.47 | 1.39 | 1.59 |
| **TCMR lesions** | | | | | |
| i (interstitial infiltrate) | 0.32 | 0.55 | 0.54 | 0.51 | 0.64 |
| t (tubulitis) | 0.30 | 0.41 | 0.42 | 0.38 | 0.44 |
| **Rejection lesions** | | | | | |
| v (vasculitis) | 0.01 | 0.08 | 0.04 | 0.14 | 0.05 |
| **Atrophy-fibrosis-related** | | | | | |
| ci (fibrosis) | 1.12 | 1.44 | 1.24 | 1.64 | 1.57 |
| ct (atrophy) | 1.03 | 1.21 | 0.98 | 1.40 | 1.45 |
| cv (fibrous intimal thickening) | 0.90 | 0.97 | 0.81 | 1.18 | 0.88 |
| ah (hyalinosis) | 1.00 | 1.19 | 1.00 | 1.25 | 1.69 |

<sup>a</sup>Main table entries indicate means, except for time posttransplant which are medians.

<sup>b</sup>TGMR archetypes are not shown.

<sup>c</sup>Proteinuria is coded as positive = 1, negative = 0. Therefore, the means for these variables indicate the fraction of biopsies that were positive. Missing values were excluded from the calculations.
cg-score rose sharply, peaked at 5 years, and plateaued. DSA and C4d positivity gradually increased in frequency over time then plateaued. The i-scores (interstitial infiltrate) and t-scores (tubulitis)—canonical lesions of TCMR—were higher in the early period (although far below the diagnostic TCMR levels) probably reflecting resolving mild injury-induced changes from transplantation (see Discussion).

We examined the transcript set and classifier scores in mABMR biopsies before and after 1 year posttransplant (Table S1). The most significant differences were related to changes that increase with time and atrophy-fibrosis—immunoglobulin transcripts (IGTs)\textsuperscript{30,31} and the atrophy-fibrosis classifier (ciProb). Some ABMR scores were also higher in biopsies after >1 year posttransplant. Among individual transcripts (Table S1), most transcripts differentially expressed between mABMR biopsies before and after 1 year were IGTs, which were increased after 1 year.

### 3.3 | DSA-negative mABMR is earlier posttransplant than DSA-positive mABMR

Table 2 shows that DSA-negative mABMR biopsies had an earlier time posttransplant than DSA-positive mABMR by \(-1.5\) years (mean 2.4 vs. 3.9 years). This difference was most significant in early-stage mABMR (EABMR). There was a similar trend in FABMR (not significant).

### 3.4 | Clinical and histologic features of DSA-negative and DSA-positive mABMR

Table 3 compares the features of 150 DSA-negative and 248 DSA-positive mABMR biopsies, plus 854 No rejection biopsies. Among clinical features, DSA-negative mABMR biopsies had a slightly lower eGFR than DSA-positive mABMR.

Among histologic lesions, DSA-negative mABMR showed lower ptc-lesions (\(p = 3 \times 10^{-3}\)) and cg-lesions (\(p = .04\)) and lower g-lesions (not significant). However, the i-scores (\(p = 1 \times 10^{-4}\)) and the t-scores (not significant) were higher in DSA-negative mABMR. DSA-negative mABMR had somewhat lower atrophy-fibrosis-related (ci- and ct-) scores and significantly lower scores for arterial fibrous intimal thickening (cv-score, \(p = .03\)) and hyalinosis (ah-score, \(p = 6 \times 10^{-3}\)).

### 3.5 | Detailed HLA antibody and DSA assessment

In 1394 biopsies with available DSA status, 42% were DSA-positive (Table 5). The mABMR biopsies were 60% DSA-positive, peaking in
FABMR: No rejection 34%; EABMR 56%; FABMR 70%; and LABMR 58%. The DSA positivity increased with ABMR activity and stage. Anti-class II was common (315/389, 81%) across all archetypal biopsy groups, even in No rejection.

The DSA-negative mABMR patients were usually sensitized: among DSA-negative patients, HLA antibody (“panel-reactive antibody” or “PRA”) was more frequent in mABMR (60%) than in No rejection (35%, $p = 5.8 \times 10^{-7}$).

TABLE 2 Time of biopsy posttransplant in DSA-negative versus DSA-positive mABMR

| Biopsy group | Time of biopsy posttransplant | DSA-negative (N = 150) | DSA-positive (N = 248) | p value for DSA-positive vs DSA-negative |
|--------------|-------------------------------|------------------------|------------------------|----------------------------------------|
| All mABMR    | Median days (years) (range in days) | 867 [2.4 year] (8–12,371) | 1408 [3.9 year] (3–9889) | $1.2 \times 10^{-3}$ |
|              | Mean days (years)              | 1698 (4.7 year)         | 2219 (6.1 year)         | $6.7 \times 10^{-4}$ |
|             | Median days (years) (range in days) | 484 [1.3 year] (8–8030) | 998 [2.7 year] (3–9466) | $4.0 \times 10^{-3}$ |
|              | Mean days (years)              | 1035 (2.8 year)         | 1846 (5.1 year)         | $3.3 \times 10^{-3}$ |
| EABMR        | Median days (years) (range in days) | 1260 [3.5 year] (72–9525) | 1610 [4.4 year] (9–9889) | 0.31 |
|              | Mean days (years)              | 1904 (5.2 year)         | 2213 (6.1 year)         | 0.32 |
| FABMR        | Median days (years) (range in days) | 2763 [7.6 year] (14–12,371) | 2690 [7.4 year] (107–8252) | 0.66 |
|              | Mean days (years)              | 3262 (8.9 year)         | 3274 (9.0 year)         | 0.29 |

Note: t-test and Wilcoxon sign rank test was used for time of biopsy posttransplant. The p value column is in italics as it compares the previous two columns. Differences $p < .01$ are shaded and the larger fraction is bolded.

TABLE 3 Clinical variables and histologic lesion scores in the No rejection (N = 854) and mABMR (N = 398) biopsies with defined DSA status with No rejection (N = 854) shown for reference

| Variable                  | Mean value or score in each archetype   |
|---------------------------|-----------------------------------------|
|                           | No rejection (N = 854)                  |
|                           | DSA-negative mABMR (N = 150)            |
|                           | DSA-positive mABMR (N = 248)            |
|                           | p value DSA-positive vs DSA-negative     |
| Clinical                  |                                         |
| eGFR (cc/min/M²)          | 45                                      |
|                          | 43                                      |
|                          | 49                                      |
|                          | 0.03                                    |
| Proteinuria              | 0.53                                    |
|                          | 0.65                                    |
|                          | 0.69                                    |
|                          | 0.46                                    |
| Donor age (years)        | 45                                      |
|                          | 42                                      |
|                          | 40                                      |
|                          | 0.64                                    |
| Recipient age (years)     | 51                                      |
|                          | 48                                      |
|                          | 49                                      |
|                          | 0.83                                    |
| ABMR lesions             | g (glomerulitis)                        | 0.28                                    |
|                          | 1.22                                    |
|                          | 1.39                                    |
|                          | 0.14                                    |
| ptc (capillaritis)       | 0.26                                    |
|                          | 1.15                                    |
|                          | 1.50                                    |
|                          | 3 x 10^{-3}                             |
| cg (double contours)     | 0.19                                    |
|                          | 0.86                                    |
|                          | 1.09                                    |
|                          | 0.04                                    |
| TCMR lesions             | i (interstitial infiltrate)             | 0.30                                    |
|                          | 0.72                                    |
|                          | 0.38                                    |
|                          | 1 x 10^{-4}                             |
| t (tubulitis)            | 0.31                                    |
|                          | 0.47                                    |
|                          | 0.33                                    |
|                          | 0.42                                    |
| Rejection lesions        | v (vasculitis)                          | 0.01                                    |
|                          | 0.04                                    |
|                          | 0.10                                    |
|                          | 0.16                                    |
| Atrophy-fibrosis-related | ci (fibrosis)                           | 1.14                                    |
|                          | 1.38                                    |
|                          | 1.52                                    |
|                          | 0.24                                    |
| ct (atrophy)             | 1.04                                    |
|                          | 1.12                                    |
|                          | 1.24                                    |
|                          | 0.26                                    |
| cv (fibrous intimal thickening) | 0.87                                |
|                          | 0.78                                    |
|                          | 1.06                                    |
|                          | 0.03                                    |
| ah (hyalinosis)          | 1.01                                    |
|                          | 0.97                                    |
|                          | 1.35                                    |
|                          | 6 x 10^{-3}                             |

Note: Differences at $p < .05$ are bolded, and at $p < .01$ are bolded and shaded. The p value column is in italics as it compares the previous two columns.

aMain table entries indicate means, except for time posttransplant which are medians.

bTCMR archetypes are not shown.

cProteinuria is coded as positive = 1, negative = 0. Therefore, the means for this variables indicate the fraction of biopsies that were positive. Missing values were excluded from the calculations.
C4d positivity is strongly related to DSA status

As in earlier analyses, C4d positivity was strongly associated with DSA positivity across all biopsy groups, even No rejection (Table 6, showing biopsies where both C4d and DSA were tested). DSA-negative mABMR was 86% C4d-negative.

Genome-wide class comparisons between DSA-negative mABMR versus DSA-positive mABMR

We used genome-wide class comparisons to compare gene expression between DSA-negative and DSA-positive mABMR. There were essentially no differences in top-ranked genes at the rigorous adjusted p < .05: only two of 49,495 probe sets were significantly...
lower in DSA-negative mABMR (Table 7), and none were signifi-
cantly higher in DSA-negative mABMR (Table S1). There were
small differences significant at unadjusted
$p$
values, all consist-
ent with lower ABMR activity and earlier stage of DSA-negative
mABMR.

### 3.8 | Comparing the top ABMR-increased transcripts in DSA-negative ABMR and in DSA-
positive mABMR

We separately identified the top genes increased in DSA-negative
mABMR versus No rejection and in DSA-positive mABMR versus No
rejection.

The top genes increased by ABMR were virtually identical in
DSA-negative and DSA-positive mABMR, both by fold change and
$p$
value (Figure 3). Figure 3A plots the top genes by fold changes in
DSA-negative mABMR on the y-axes, against those in DSA-positive
mABMR on the x-axis. Each dot represents a probe set. *IFNG-
inducible* chemokines *CXCL9/10/11*, as well as NK genes such as
*CCL4* and *GNLY*, were most strongly increased in both DSA-negative
and DSA-positive mABMR. The fold changes are slightly lower in
DSA-negative i.e. lower intensity. Figure 3B plots the top genes by
$p$
value. The most significantly increased genes in both DSA-negative
and DSA-positive mABMR were NK genes and *IFNG*-inducible
genes. The $p$
values are lower in DSA-negative mABMR, probably
reflecting fewer biopsies and lower intensity.

The findings were similar when we used histologic diagnoses of
ABMR (Figure 3C and D).

The top 10 ABMR-associated genes by $p$
value were listed for
DSA-positive mABMR in Table 8 and DSA-negative mABMR in
Table 9. In both DSA-negative and DSA-positive mABMR, 13 of the
top 20 genes were NK expressed.

The findings were similar in fully developed mABMR: the top
genes in DSA-positive FABMR (Table S1) and DSA-negative FABMR
(Table S1) were nearly identical, dominated by the same NK cell-
associated transcripts (shaded and bolded) and *IFNG*-inducible
transcripts.

The top 10 increased transcripts shared between DSA-positive
and DSA-negative mABMR and FABMR are summarized and com-
pared in Table 10, showing that many of the top 10 are shared, and
most are NK cell-associated.

### Table 5 DSA detail in population with available DSA status (1394 tested of 1679 total) and in No rejection and mABMR

| Biopsy group | Total | DSA-negative | DSA-negative/ PRA-negative | Total DSA-positive (% of column total) | DSA Class I | DSA Class I/II | DSA Class II | DSA-class not recorded |
|--------------|-------|-------------|---------------------------|----------------------------------------|-----------|--------------|-------------|------------------------|
| All          | 1394  | 807 (58%)   | 277                       | 587 (42%)                              | 74        | 113          | 202         | 198                    |
| No rejection | 854   | 566 (66%)   | 169                       | 288 (34%)                              | 38        | 45           | 103         | 102                    |
| All mABMR    | 398   | 150 (40%)   | 75                        | 248 (60%)                              | 31        | 56           | 74          | 56                     |
| EABMR        | 177   | 77 (44%)    | 40                        | 100 (56%)                              | 13        | 19           | 26          | 42                     |
| FABMR        | 159   | 47 (30%)    | 23                        | 112 (70%)                              | 13        | 31           | 34          | 3                     |
| LABMR        | 62    | 26 (42%)    | 12                        | 36 (58%)                               | 5         | 6            | 14          | 11                    |

*aThe totals for the PRA-negative plus PRA-positive are less than the total DSA-negative because not all DSA-negative results had PRA results
reported.*

*bChi-square for fraction DSA-negative/PRA-positive with No rejection (169/478 or 35%) versus DSA-negative/PRA-positive with mABMR (75/125 or 60%): $p = 5.79 \times 10^{-7}$. 

| Number of biopsies C4d-positive as fraction (%) of biopsies tested for both C4d and DSA |
|-----------------------------------------------|-----------------------------------------------|
| DSA-negative | DSA-positive | Fisher's test $p$ value of DSA status versus C4d status |
|----------------|--------------|-----------------------------------------------|
| All biopsies   | 48/632 (8%)  | 151/493 (31%) | $7 \times 10^{-24}$                          |
| No rejection   | 29/444 (7%)  | 42/234 (18%) | $9 \times 10^{-6}$                          |
| All mABMR      | 16/116 (14%) | 98/224 (44%) | $1 \times 10^{-8}$                          |
| EABMR          | 7/64 (11%)   | 36/92 (40%)  | 0.0001                                      |
| FABMR          | 6/32 (19%)   | 53/100 (53%) | 0.0009                                      |
| LABMR          | 3/20 (15%)   | 9/32 (28%)   | 0.33                                        |

*aDSA-negative mABMR was more often C4d-positive than DSA-negative No rejection ($p = .02$).
3.9 | Survival

We calculated death-censored graft survival at 3 years post-biopsy based on one random biopsy per transplant (Figure 4). Figure 4A shows that EABMR had better survival than FABMR or LABMR, as in earlier analyses.12 Within each mABMR group or in all mABMR, DSA status (negative, positive, or unknown) had little impact on graft survival: in EABMR (Figure 4B), FABMR (Figure 4C), LABMR (Figure 4D), or all mABMR (Figure 4E). Similarly DSA status did not predict survival in No rejection (Figure 4F), similar to our previous report.24 Thus, the presence of mABMR and the stage of mABMR affect survival after biopsy, but DSA status does not.

3.10 | How does DSA-negative mABMR transition over time?

Establishing whether DSA-negative mABMR transitions to DSA-positive mABMR (and vice versa) or no rejection cannot be formally answered in this cross-sectional study of indication biopsies because follow-up biopsies are not generally indicated as SOC. The fact that DSA-positivity rises in the ABMR population from EABMR to FABMR before falling in LABMR complicates this question.

However, among the relatively few ABMR patients with later biopsies, in most pairs, the DSA status remained the same in the second biopsy. DSA-negative mABMR transitioned to DSA-positive mABMR more often (8/32 = 25%) than the reverse (DSA-positive

| TABLE 7 | Top 20 increased genes differing between DSA-positive and DSA-negative mABMR |
|---------|-------------------|-----------------|---------|---------|---------|---------|
| Gene symbol | Gene name | Transcript set annotation | p value | FDR | DSA-negative | DSA-positive | No rejection |
| P2RX7 | Purinergic receptor P2X, ligand-gated ion channel, 7 | IFNG-inducible (GRIT) | $1 \times 10^{-6}$ | 0.03 | 29 | 33 | 26 |
| TM4SF18 | Transmembrane 4 L six family member 18 | ABMR-RAT | $1 \times 10^{-6}$ | 0.03 | 423 | 497 | 331 |
| ITGAL | Integrin, alpha L (antigen CD11A [p180], lymphocyte function-associated antigen 1; alpha polypeptide) | ABMR-RAT | $4 \times 10^{-5}$ | 0.05 | 36 | 39 | 32 |
| STAT2 | Signal transducer and activator of transcription 2, 113 kDa | IFNG-inducible (GRIT) | $4 \times 10^{-6}$ | 0.05 | 63 | 68 | 59 |
| UVSSA | UV-stimulated scaffold protein A | ABMR-RAT | $7 \times 10^{-6}$ | 0.07 | 50 | 55 | 51 |
| ROBO4 | Roundabout, axon guidance receptor, homolog 4 (Drosophila) | ABMR-RAT | $3 \times 10^{-5}$ | 0.14 | 844 | 964 | 597 |
| TNFRSF14 | Tumor necrosis factor receptor superfamily, member 14 | IFNG-inducible (GRIT) | $4 \times 10^{-5}$ | 0.17 | 475 | 513 | 433 |
| SEMA3D | Sema domain, immunoglobulin domain (lg), short basic domain, secreted (semaforin) 3D | ABMR-RAT | $6 \times 10^{-5}$ | 0.17 | 84 | 101 | 80 |
| COL13A1 | Collagen, type XIII, alpha 1 | ABMR-RAT | $7 \times 10^{-5}$ | 0.17 | 50 | 58 | 38 |
| CACTIN | Cactin, spliceosome C complex subunit | ABMR-RAT | $8 \times 10^{-5}$ | 0.18 | 211 | 224 | 213 |
| LILR A1 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1 | ABMR-RAT | $9 \times 10^{-5}$ | 0.18 | 77 | 85 | 69 |
| KRT36 | Keratin 36 | ABMR-RAT | $1 \times 10^{-4}$ | 0.19 | 19 | 20 | 20 |
| CX3CR1 | Chemokine (C-X3-C motif) receptor 1 | ABMR-RAT | $1 \times 10^{-4}$ | 0.19 | 442 | 531 | 212 |
| ALKBH6 | alkB, alkylation repair homolog 6 (E. coli) | ABMR-RAT | $1 \times 10^{-4}$ | 0.21 | 120 | 128 | 129 |
| THEMIS2 | Thymocyte selection associated family member 2 | IFNG-inducible (GRIT) | $2 \times 10^{-4}$ | 0.21 | 118 | 127 | 104 |
| HLA-B | Major histocompatibility complex, class I, B | IFNG-inducible (GRIT) | $2 \times 10^{-4}$ | 0.21 | 81 | 93 | 67 |
| LYPD2 | LY6 | ABMR-RAT | $2 \times 10^{-4}$ | 0.23 | 47 | 51 | 48 |
| AURKAPS1 | Aurora kinase A pseudogene 1 | ABMR-RAT | $2 \times 10^{-4}$ | 0.23 | 541 | 570 | 563 |
| SPN | Sialophorin | ABMR-RAT | $2 \times 10^{-4}$ | 0.23 | 96 | 103 | 83 |
| ARAP3 | ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 | IFNG-inducible (GRIT) | $3 \times 10^{-4}$ | 0.23 | 115 | 124 | 111 |

Note: Gray shading signifies p < .05 FDR. Abbreviation: FDR, false discovery rate.
**FIGURE 3** Scatterplots showing probe set (A) fold change in DSA-negative mABMR biopsies versus No rejection biopsies (y-axis) and DSA-positive mABMR biopsies versus No rejection biopsies (x-axis); (B) p values for the same class comparisons; (C) fold change in DSA-negative histologic ABMR biopsies versus histologic Normal/AKI biopsies (y-axis) and DSA-positive histologic ABMR biopsies versus histologic Normal/AKI biopsies (x-axis); and (D) p values for the same class comparisons. Blue dashes show the 1:1 line in each plot.

**TABLE 8** Top 20 genes by p value increased in DSA-positive mABMR (E, F, L, N = 248) versus No rejection

| Gene symbol | Gene name                                      | Transcript set annotation          | p value  | FDR    | No rejection | DSA-positive mABMR |
|-------------|------------------------------------------------|------------------------------------|----------|--------|--------------|-------------------|
| KLRD1       | Killer cell lectin-like receptor subfamily D, member 1 | NK; ABMR-RAT                       | $2 \times 10^{-227}$ | $1 \times 10^{-222}$ | 41              | 96                |
| GNLY        | Granulysin                                     | NK; ABMR-RAT                       | $8 \times 10^{-223}$ | $1 \times 10^{-218}$ | 53              | 208               |
| PLA1A       | Phospholipase A1 member A                      | IFNG-inducible (GRIT)              | $4 \times 10^{-216}$ | $3 \times 10^{-212}$ | 231             | 623               |
| PRF1        | Perforin 1 (pore forming protein)              | NK; ABMR-RAT                       | $2 \times 10^{-208}$ | $1 \times 10^{-204}$ | 87              | 180               |
| CCL4        | Chemokine (C-C motif) ligand 4                 | NK; ABMR-RAT                       | $8 \times 10^{-183}$ | $4 \times 10^{-179}$ | 73              | 331               |
| WARS        | Tryptophanyl-tRNA synthetase                   | IFNG-inducible (GRIT)              | $7 \times 10^{-180}$ | $3 \times 10^{-176}$ | 557             | 1108              |
| FGFBP2      | Fibroblast growth factor binding protein 2     | NK; ABMR-RAT                       | $3 \times 10^{-169}$ | $1 \times 10^{-165}$ | 40              | 102               |
| GBP4        | Guanylate binding protein 4                    | IFNG-inducible (GRIT)              | $4 \times 10^{-167}$ | $1 \times 10^{-163}$ | 225             | 570               |
| S1PR5       | Sphingosine-1-phosphate receptor 5             | NK; ABMR-RAT                       | $7 \times 10^{-166}$ | $2 \times 10^{-162}$ | 19              | 30                |
| NKG7        | Natural killer cell group 7 sequence           | NK; ABMR-RAT                       | $2 \times 10^{-165}$ | $5 \times 10^{-162}$ | 164             | 293               |
| TRDV3       | T cell receptor delta variable 3               | NK; ABMR-RAT                       | $2 \times 10^{-164}$ | $4 \times 10^{-161}$ | 13              | 31                |
| CXCL11      | Chemokine (C-C motif) ligand 11                | IFNG-inducible (GRIT)              | $2 \times 10^{-163}$ | $4 \times 10^{-160}$ | 20              | 165               |
| TRDC        | T cell receptor delta constant                 | NK; ABMR-RAT                       | $3 \times 10^{-161}$ | $6 \times 10^{-158}$ | 52              | 131               |
| LYPD5       | LY6                                            | ABMR-RAT                           | $2 \times 10^{-158}$ | $4 \times 10^{-155}$ | 16              | 30                |
| CD160       | CD160 molecule                                 | NK; ABMR-RAT                       | $1 \times 10^{-153}$ | $2 \times 10^{-150}$ | 25              | 63                |
| CCL4L1      | Chemokine (C-C motif) ligand 4-like 1          | NK; ABMR-RAT                       | $5 \times 10^{-153}$ | $8 \times 10^{-150}$ | 28              | 92                |
| KLRF1       | Killer cell lectin-like receptor subfamily F, member 1 | ABMR-RAT, NKB | $6 \times 10^{-153}$ | $9 \times 10^{-150}$ | 22              | 41                |
| IDO1        | Indoleamine 2,3-dioxygenase 1                  | IFNG-inducible (GRIT)              | $2 \times 10^{-151}$ | $3 \times 10^{-148}$ | 103             | 452               |
| SH2D1B      | SH2 domain containing 1B                      | NK; ABMR-RAT, NKB                  | $3 \times 10^{-144}$ | $4 \times 10^{-141}$ | 12              | 24                |
| GBP1        | Guanylate binding protein 1, interferon-inducible | IFNG-inducible (GRIT)              | $1 \times 10^{-143}$ | $2 \times 10^{-140}$ | 305             | 870               |

Note: Gray shading signifies NK cell-expressed genes. Abbreviation: FDR, false discovery rate.
that DSA-negative ABMR can sometimes be “transient.”

### Table 9: Top 20 genes by p value increased in DSA-negative mABMR (E, F, L, N = 150) versus No rejection

| Gene symbol | Gene name                                      | Transcript set annotation | p value       | FDR           | No rejection | DSA-negative mABMR |
|-------------|-----------------------------------------------|----------------------------|---------------|---------------|--------------|-------------------|
| GNLY        | Granulysin                                    | ABMR-RAT                   | $4.17 \times 10^{-144}$ | $2.07 \times 10^{-129}$ | 53           | 182               |
| KLRD1       | Killer cell lectin-like receptor subfamily D, member 1 | ABMR-RAT                   | $2.18 \times 10^{-133}$ | $3.60 \times 10^{-129}$ | 33           | 75                |
| PRF1        | Perforin 1 (pore forming protein)             | ABMR-RAT                   | $8.66 \times 10^{-128}$ | $8.57 \times 10^{-124}$ | 87           | 165               |
| PLA1A       | Phospholipase A1 member A                     | IFNG-inducible (GRIT)      | $4.87 \times 10^{-125}$ | $3.44 \times 10^{-121}$ | 231          | 549               |
| FGFBP2      | Fibroblast growth factor binding protein 2    | ABMR-RAT                   | $3.78 \times 10^{-107}$ | $1.87 \times 10^{-103}$ | 40           | 93                |
| WARS        | Tryptophanyl-tRNA synthetase                  | IFNG-inducible (GRIT)      | $1.80 \times 10^{-103}$ | $8.11 \times 10^{-100}$ | 640          | 1196              |
| CCL4        | Chemokine (C-C motif) ligand 4                | ABMR-RAT                   | $2.77 \times 10^{-102}$ | $1.05 \times 10^{-98}$ | 73           | 276               |
| NKG7        | Natural killer cell group 7 sequence          | ABMR-RAT                   | $1.61 \times 10^{-101}$ | $5.70 \times 10^{-98}$ | 164          | 275               |
| KLRC3       | Killer cell lectin-like receptor subfamily C, member 3 | ABMR-RAT                   | $1.67 \times 10^{-99}$ | $5.51 \times 10^{-96}$ | 7            | 14                |
| TRDV3       | T cell receptor delta variable 3              | ABMR-RAT                   | $1.91 \times 10^{-98}$ | $5.91 \times 10^{-95}$ | 13           | 27                |
| CXCL11      | Chemokine (C-X-C motif) ligand 11             | IFNG-inducible (GRIT)      | $6.10 \times 10^{-98}$ | $1.78 \times 10^{-94}$ | 20           | 142               |
| S1PR5       | Sphingosine-1-phosphate receptor 5            | ABMR-RAT                   | $2.38 \times 10^{-96}$ | $6.21 \times 10^{-93}$ | 19           | 27                |
| CD160       | CD160 molecule                                | ABMR-RAT                   | $7.45 \times 10^{-95}$ | $1.76 \times 10^{-91}$ | 25           | 56                |
| GBP4        | Guanylate binding protein 4                   | IFNG-inducible (GRIT)      | $9.55 \times 10^{-92}$ | $1.97 \times 10^{-88}$ | 225          | 507               |
| KLRF1       | Killer cell lectin-like receptor subfamily F, member 1 | ABMR-RAT, NKB            | $1.46 \times 10^{-91}$ | $2.90 \times 10^{-88}$ | 22           | 38                |
| GZMB        | Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) | ABMR-RAT                   | $4.12 \times 10^{-89}$ | $7.29 \times 10^{-86}$ | 56           | 149               |
| TRDC        | T cell receptor delta constant                | ABMR-RAT                   | $4.58 \times 10^{-89}$ | $7.82 \times 10^{-86}$ | 39           | 120               |
| IDO1        | Indoleamine 2,3-dioxygenase 1                 | IFNG-inducible (GRIT)      | $4.97 \times 10^{-89}$ | $8.20 \times 10^{-86}$ | 103          | 400               |
| KLRC1       | Killer cell lectin-like receptor subfamily C, member 1 | ABMR-RAT                   | $3.27 \times 10^{-85}$ | $4.76 \times 10^{-82}$ | 15           | 41                |
| GBP1        | Guanylate binding protein 1, interferon-inducible | IFNG-inducible (GRIT) | $3.19 \times 10^{-81}$ | $4.16 \times 10^{-78}$ | 305          | 780               |

Note: Gray shading signifies NK cell-expressed genes. Abbreviation: FDR, false discovery rate.

mABMR to DSA-negative mABMR 5/61 = 8.2%). In terms of transitions to no rejection, more DSA-negative mABMR (12/32) transitioned to no rejection, compared with 10/57 DSA-positive ABMR (p = .036, Chi-square test), compatible with previous observations that DSA-negative ABMR can sometimes be “transient.”

## 4 Discussion

This study defined the relationship between DSA status and the timing, histology, C4d, molecular features, and outcomes in mABMR. DSA and C4d positivity were most frequent in the most active mABMR state – FABMR. C4d was strongly associated with DSA even in No rejection biopsies. As previously reported, DSA-negative mABMR usually occurred in sensitized patients – 60% were PRA-positive. Compared with DSA-positive mABMR, DSA-negative mABMR was earlier posttransplant, mostly C4d-negative, and had milder ABMR activity, for example, lower ptc-lesion scores and ABMR-related transcript set and classifier scores. In genome-wide class comparisons, we were unable to find genes with significantly different expression in DSA-negative versus DSA-positive mABMR. Moreover, despite lower activity, DSA-negative mABMR had the same top mABMR-associated genes as DSA-positive mABMR, suggesting that the mechanisms were the same and extending the previous finding of transcript similarity. DSA-negative mABMR had comparable effects on graft loss compared with DSA-positive mABMR.

These results using exclusively molecular definitions of ABMR confirm some findings in studies of ABMR biopsies defined by histologic MVI. These studies also found that DSA-negative ABMR
was earlier than DSA-positive and sometimes transient, and less frequently C4d-positive. Unlike the present study the histologic MVI cases had a survival advantage over DSA-positive ABMR. However, our mABMR cases were later on average than in histologic MVI cases. The differences could be influenced by the use of MVI to define ABMR. Especially in early biopsies, we have previously noted that some histologic MVI (ptc- and g-lesions) may be mABMR-negative and possibly related to other microvascular injuries. The diagnosis of ABMR is challenging in the early posttransplant period and more studies comparing the details of MVI and mABMR changes during this time are needed.

DSA interpretation even in expert laboratories is often challenging. The INTERCOMEX study uses SOC definitions of DSA by the local laboratory because there is no universal agreement on what technologies and cutoffs should be used. Donor-recipient HLA genotyping may be incomplete; interpretation of DSA can differ among local laboratories; and there is no central “gold standard.” Technical challenges include non-specific bead reactivity, batch variation in bead manufacture, prozones, bead saturation, and limited reproducibility of quantitation (mean fluorescence intensity). Moreover, it remains difficult to predict the pathogenicity of a DSA, in part due to the lack of understanding of the conditions that IgG must meet to be “ABMR-effector-competent” (see below). Complement-binding DSA assays introduced to identify pathogenic DSA have not proven to be consistently superior to conventional DSA testing. Moreover, mABMR can be subtle: subthreshold molecular mABMR-like changes associated with DSA are demonstrable in some biopsies currently considered to have no rejection. The future classification of ABMR is likely to be increasingly based on recognizing gradients beyond the current “binary” approaches.

C4d staining is negative in most DSA-negative biopsies in both histologic and molecular ABMR, and this observation invites us to reconsider the relationship of C4d staining to both the DSA status and the ABMR disease state. C4d deposition is strongly linked to DSA but can occur without HLA DSA or ABMR: for example, diffuse C4d staining occurs in ABO incompatibility without ABMR and is induced by monoclonal antibody bamlanivimab without ABMR. We suggest that C4d deposition and ABMR are often associated but actually represent independent molecular processes: C4d requires widespread binding of many DSA IgGs that may or may not include ABMR-effector-competent IgGs, whereas ABMR is mediated by relatively small numbers of ABMR-effector-competent IgGs that may or may meet the requirements for C4d deposition.

Because AKI molecular changes regress and atrophy-fibrosis changes progress over many months posttransplant, DSA-negative mABMR being 1.5 years earlier will have more unresolved

| Biopsy groups compared                              | Top 10 genes (by p value) increased |
|-----------------------------------------------------|-----------------------------------|
| All mABMR                                           | KLRD1, GNLY, PLA1A, PRF1,          |
|                                                     | CCL4, WARS, FGBP2, GBP4, S1PR5, NKG7 |
| All DSA-negative mABMR versus No rejection          | GNLY, KLRD1, PRF1, PLA1A,          |
|                                                     | FGBP2, WARS, CCL4, NKG7, KLRC3, TRDV3 |
| Full-developed mABMR                                 | KLRD1, LYPD5, GNLY, WARS, PLA1A, |
| DSA-positive FABMR versus No rejection               | PRF1, S1PR5, TRDV3, KLRC3, KLRF1  |
| DSA-negative FABMR versus No rejection               | LYPD5, PLA1A, WARS, KLRD1, PRF1, |
|                                                     | GNLY, KLRC3, S1PR5, SH2D1B, KLRF1 |

Note: NK-associated transcripts are bolded and underlined.

aThe top decreased genes were less significant but two endothelial cell genes (ESM1 and F8) were highly ranked in the top 10 decreased in all.

*bGenes common between DSA-positive top 10 and DSA-negative top 10 mABMR versus No rejection genes are underlined, bolded, and italicized.

TABLE 10 Top genes increased in expression in all mABMR (E, F, L) and in FABMR, compared with No rejection

Note: NK-associated transcripts are bolded and underlined.

aThe top decreased genes were less significant but two endothelial cell genes (ESM1 and F8) were highly ranked in the top 10 decreased in all.

*bGenes common between DSA-positive top 10 and DSA-negative top 10 mABMR versus No rejection genes are underlined, bolded, and italicized.
AKI-related change and less time and stage-related features such as cg-lesions, hyalinosis, and arterial fibrous intimal thickening. The i- and t-scores are slightly higher in DSA-negative mABMR but not close to being diagnostic for TCMR, and combined with the negative TCMRProb scores suggest the residual effects of AKI in the transplant process. The elevated FICOL transcripts, which are induced by transplant AKI and regress slowly over the first several years, also support this interpretation.

Alternative explanations for DSA-negative mABMR are not necessarily mutually exclusive because there may be several ways that ABMR can occur without DSA being identified. As listed in the introduction, these include incomplete donor genotyping, complete absorption of DSA by kidney, DSA directed against non-HLA alloantigens, autoantibody such as AT1R, and antibody-independent NK cell recognition of missing self. This study cannot dismiss any of the proposed explanations. However, the absence of PRA in 40% of DSA-negative mABMR cases excludes inadequate genotyping in these cases. The high protection that perfect HLA-matching provides against mABMR, and the high success of the national distribution program for 100% sensitized people argue that the targets of the missing antibody in DSA-negative mABMR cases are mostly HLA alloantigens. But rare cases of non-HLA-encoded polymorphic molecules on capillary endothelium can probably evoke an ABMR-effector-competent alloantibody and mediate mABMR in highly sensitized patients without a DSA being detectable by existing tests. As stated earlier, the possibility that important high-affinity DSAs are absorbed by the kidney has not been supported by elution studies.

Autoantibodies are common in chronic diseases causing tissue injury and their role in pathogenesis is often controversial. Autoantibodies often accompany mABMR and DSA are frequently associated with DSA, and their role is being discussed in the ongoing STAR process. Some issues make them unlikely to be the principal explanation of DSA-negative mABMR: for example, it is...
not clear how these autoantibodies distinguish autoantigen in 150 g of donor tissue from that in the much more abundant host tissue (e.g., 70000 g). Moreover, autoantibodies before transplant have not been shown to predict the development of ABMR posttransplant. However, synergy between DSA and autoantibodies such as AT1R in ABMR must be considered. 22,49

It is possible we are not detecting all the effects of antibody against donor antigens by the existing histologic and molecular approaches. 50– 52 A different type of antibody-mediated stress could exist in a minority of cases that evades the current definitions. ABMR-like stress is capable of operating over a very long period at a low level, as we previously published. 24

The present study does not suggest that any unique mechanisms are operating only in DSA-negative mABMR. For example, if DSA-negative ABMR was mediated only by “missing self” receptor recognition, and DSA-positive ABMR only by Fc receptor triggering by DSA, we would have expected some differences in the ABMR-associated genes. The striking association of NK cell transcripts with all ABMR 52 is compatible with a role of missing-self triggering of NK cells. 16,17 potentially augmenting Fc receptor recognition of bound DSA. Although the present class comparisons cannot exclude a unique mechanism operating only in DSA-negative mABMR, our working hypothesis pending new evidence is that DSA-positive and DSA-negative ABMR use the same mechanisms i.e. Fc receptor triggering by an ABMR-effector competent DSA (detectable or not) possibly augmented by missing self receptor triggering.

These results summarized in Table 11 suggest a model compatible with the literature. In the model, the mechanisms of all ABMR—DSA-negative and positive—are the same, involving NK cell triggering by CD16a Fc receptors plus missing-self recognition. ABMR is mediated by ABMR-effector-competent donor-specific IgG, which assembles IgG-antigen multimers on the endothelium that in turn assemble Fc receptor multimers for NK activation. 53 C1q binding by IgG does require IgG hexamers for activating C1q 37, and we suggest that ABMR-effector-competence also requires multimerization. ABMR-effector-competent IgGs can appear early in DSA production before circulating DSA and C4d deposition is detectable. Some ABMR-effector-competent DSA may escape detection by bead assays because the configuration of immobilized HLA proteins on beads does not simulate the dynamic expression on endothelium required for multimerization and Fc receptor triggering. ABMR-effector-competent IgGs increase with time, accompanied by the larger DSA response (epitope spreading), making circulating DSA and C4d deposition detectable. Circulating DSA often accompanies ABMR-effector-competent DSA IgG but is neither sufficient nor necessary. 24

The goal 14 of treatment should be suppression of mABMR activity and arrest of disease progression. Suppression of measured DSA if present could also be a useful surrogate, assuming that treatments effective for suppressing DSA will also control the ABMR-effector-competent IgG. However, merely converting DSA-positive ABMR to DSA-negative ABMR will not benefit patients unless there is other evidence for disease modification. Potential strategies for reducing all DSA, including ABMR-effector-competent DSA, include targeting the neonatal Fc receptor, 54,55 proteasome inhibition, anti-IL6 56 or anti-IL6 receptor, 57 and plasma cell depleting monoclonals such as anti CD38 - daratumumab 58 or felzartamab. (A trial of felzartamab is beginning—ClinicalTrials.gov #NCT05021484.) Direct targeting of NK cell Fc receptors or missing-self receptors should be considered in both DSA-positive and DSA-negative ABMR. Complement inhibition will probably not be effective. For example, classical complement pathway inhibition by anti-C1s monoclonal antibody BIVV009 in established mABMR reduced C4d staining but not mABMR activity. 59

In summary, the processes operating in DSA-negative ABMR are highly similar to DSA-positive ABMR. Examination of genome-wide transcript expression, gene sets, classifiers, and clinical and histologic features found differences in intensity, timing, stage, and C4d but no evidence for major mechanistic differences. This strategy cannot exclude all mechanistic differences but should have revealed major differences if they existed. Therefore, we find no evidence to suggest that the management should be different for DSA-negative versus DSA-positive ABMR. With this in mind, DSA-negative ABMR should be included in clinical ABMR trials (presumably stratified). Finally, definitive studies on the mechanisms operating in both DSA-positive and DSA-negative ABMR remain an important target for the development of new interventions to improve management and outcomes.

ACKNOWLEDGMENTS

This research has been principally supported by grants from Genome Canada, Canada Foundation for Innovation, the University of Alberta Hospital Foundation, the Alberta Ministry for Health, and the Alberta Heritage Foundation for Medical Research. We would like to acknowledge the support of the University of Alberta Hospital Foundation, the Alberta Ministry for Health, and the Alberta Heritage Foundation for Medical Research.

TABLE 11 Summary of features of DSA-negative mABMR compared with DSA-positive mABMR

| Feature                                                                 | DSA-negative mABMR | DSA-positive mABMR |
|------------------------------------------------------------------------|--------------------|--------------------|
| Earlier on average by about 1.5 years (2.4 years versus 3.9 years for DSA-positive) |                    |                    |
| Mostly sensitized: 60% PRA-positive (higher than in No rejection)        |                    |                    |
| Almost all (86%) are C4d-negative (versus 56% for DSA-positive)          |                    |                    |
| Less histologic and molecular activity                                 |                    |                    |
| Mildly elevated i-score (not diagnostic for TCMR) and fibrillar collagen transcript set score compared to DSA-positive mABMR probably reflecting earlier time posttransplant |                    |                    |
| Three-year graft survival is similar to DSA-positive                    |                    |                    |

Suggested model for DSA-negative and DSA-positive ABMR compatible with current data:

- Same mechanisms for DSA-positive and DSA-negative ABMR
- NK FcR triggering plus missing self recognition
- FcR triggering requires IgG-antigen multimers to assemble FcR multimers for triggering
- Specialized IgG DSA may appear early in DSA production before for circulating DSA and C4d deposition are detectable
- Natural history: progression as DSA-negative; evolution to DSA-positive; spontaneous resolution

This model incorporates the key findings of the study, including the role of natural killer (NK) cells and the importance of missing self recognition in the pathogenesis of ABMR. The model also highlights the similarities between DSA-negative and DSA-positive ABMR, suggesting that both mechanisms are driven by immune responses against donor-specific antigens.

In summary, the study contributes to our understanding of ABMR by providing evidence for the involvement of novel immune pathways, particularly those involving NK cells and missing self recognition. These findings have implications for the development of new therapeutic strategies aimed at suppressing ABMR and improving transplant outcomes.
of Advanced Education and Technology, the Mendez National Institute of Transplantation Foundation, and Industrial Research Assistance Program. Partial support was also provided by funding from a licensing agreement with the One Lambda division of Thermo Fisher. Dr. Halloran held a Canada Research Chair in Transplant Immunology until 2008 and currently holds the Muttart Chair in Clinical Immunology.

We thank our valued clinicians in the INTERCOMEX study group who participated with us for this study by contributing biopsies and feedback (Michael Picton, Timm Heinbokel, Harold Yang, Seth Narins, Carmen Lefaucheur, Alexandre Loupy, Marek Myslak, Bertram Kasiske, Arthur Matas, and Arjang Djamali).

**DISCLOSURE**

The authors of this manuscript have conflicts of interest to disclose as described by the *American Journal of Transplantation*. P.F. Halloran holds shares in Transcriptome Sciences Inc., a University of Alberta research company dedicated to developing molecular diagnostics, supported in part by a licensing agreement between TSI and Thermo Fisher, and by a research grant from Natera. P.F. Halloran is a consultant to Natera. The other authors have declared no conflict of interest exists.

**DATA AVAILABILITY STATEMENT**

CEL files are available on the Gene Expression Omnibus website (GSE124203).

**ORCID**

Philip F. Halloran [https://orcid.org/0000-0003-1371-1947]

Gaurav Gupte [https://orcid.org/0000-0002-7600-912X]

Ondrej Víklický [https://orcid.org/0000-0003-1919-1970]

Agnieszka Perkowska-Ptasinska [https://orcid.org/0000-0001-5524-3534]

**REFERENCES**

1. Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. *Am J Transplant*. 2018;18(2):293-307.

2. Loupy A, Haas M, Roufosse C, et al. The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. *Am J Transplant*. 2020;20(9):2318-2331.

3. Halloran PF, Wadgymar A, Ritchie S, Falk J, Soleon K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. *Transplantation*. 1990;49(1):85-91.

4. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. *J Am Soc Nephrol*. 2002;13(4):1091-1099.

5. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. *J Am Soc Nephrol*. 2002;13(9):2371-2380.

6. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. *J Am Soc Nephrol*. 1999;10(10):2208-2214.

7. Maluuyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. *J Am Soc Nephrol*. 2001;12(3):574-582.

8. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microrcirculation injury is the major cause of late kidney transplant failure. *Am J Transplant*. 2009;9(11):2520-2531.

9. Halloran PF, Chang J, Fanuski K, et al. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. *J Am Soc Nephrol*. 2015;26(7):1711-1720.

10. Sis B, Allanach K, Bunnag S, Mueller TFF, Halloran PF. Microarrays detect deteriorating C4d(-) human renal allografts with ongoing antibody-mediated injury. *Am J Transplant*. 2008;8:275.

11. Halloran PF, Fanuski KS, Chang J. A probabilistic approach to histologic diagnosis of antibody-mediated rejection in kidney transplant biopsies. *Am J Transplant*. 2017;17(1):129-139.

12. Reeve J, Bohmig GA, Eskandary F, et al. Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. *JCI Insight*. 2017;2(12):e94197.

13. Senev A, Coemans M, Lerut E, et al. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome. *Am J Transplant*. 2019;19(3):763-780.

14. Callemeyn J, Lerut E, de Looor H, et al. Translational changes in kidney allografts with histology of antibody-mediated rejection without anti-HLA donor-specific antibodies. *J Am Soc Nephrol*. 2020;31(9):2168-2183.

15. Callemeyn J, Senev A, Coemans M, et al. Missing self-induced microvascular rejection of kidney allografts: a population-based study. *J Am Soc Nephrol*. 2021;32(8):2070-2082.

16. Koenig A, Mezaache S, Callemeyn J, et al. Missing self-induced activation of NK cells combines with non-complement-fixing donor-specific antibodies to accelerate kidney transplant loss in chronic antibody-mediated rejection. *J Am Soc Nephrol*. 2021;32(2):479-494.

17. Koenig A, Chen CC, Marciais A, et al. Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants. *Nat Commun*. 2019;10(1):5350.

18. Bachelet T, Couzi L, Lepreux S, et al. Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome. *Am J Transplant*. 2013;13(11):2781-3051.

19. Cahan A. Diagnosis is driven by probabilistic reasoning: counterpoint. *Diagnosis (Berl)*. 2016;3(3):99-101.

20. Dragun D, Catar R, Philippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. *Curr Opin Organ Transplant*. 2014;18(4):430-435.

21. Tanaka T, Ebata T, Tajima A, Kinoshita K, Okumura K, Yagita H. Beta2-microglobulin required for cell surface expression of blasto-cyst MHC. *Biochem Biophys Res Commun*. 2005;332(1):311-317.

22. Lefaucheur C, Viglietti D, Bouatou Y, et al. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. *Kidney Int*. 2019;96(1):189-201.

23. Jackson AM, Wiebe C, Hickey MJ. The role of non-HLA antibodies in solid organ transplantation: a complex deliberation. *Curr Opin Organ Transplant*. 2020;25(6):536-542.

24. Madill-Thomsen KS, Bohmig GA, Bromberg J, et al. Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection. *J Am Soc Nephrol*. 2021;32(11):2743-2758.

25. Halloran PF, Reeve J, Akalin E, et al. Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study. *Am J Transplant*. 2017;17(11):2851-2862.
26. Reeve J, Madill-Thomsen KS, Halloran PF, INTERCOMEX Study Group. Using ensembles of machine learning classifiers to maximize the accuracy and stability of molecular biopsy interpretation. *Am J Transplant*. 2019;19(5S):452-453.

27. RCT. (2019) R: A language and environment for statistical computing. R Foundation for statistical Computing. [http://www.r-project.org/](http://www.r-project.org/). Published 2019. Accessed.

28. Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. 2015;43(7):e47.

29. Madill-Thomsen K, Perkowska-Ptasinska A, Bohmig GA, et al. Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies. *Am J Transplant*. 2020;20(5):1341-1350.

30. Einecke G, Reeve J, Mengel M, et al. Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. *Am J Transplant*. 2008;8(7):1434-1443.

31. Venner JM, Famulski KS, Reeve J, Chang J, Halloran PF. Relationships among injury, fibrosis, and time in human kidney transplants. *JCImmunol*. 2016;11(1):e85323.

32. Halloran PF, Sellares J. Microcirculation lesions alone are not reliable for identifying antibody-mediated rejection. *Am J Transplant*. 2013;13(7):1931-1932.

33. Cornell LD. Histopathologic features of antibody mediated rejection: the Banff classification and beyond. *Front Immunol*. 2021;12(3918):718122.

34. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. *Am J Transplant*. 2013;13(7):1859-1870.

35. Tambur AR, Campbell P, Claas FH, et al. Sensitization in transplantation: assessment of risk (STAR) 2017 working group meeting report. *Am J Transplant*. 2018;18(7):1604-1614.

36. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation. *Am J Transplant*. 2013;13(11):3050-3051.

37. Diebold CA, Beurskens FJ, de Jong RN, et al. Complement is activated by IgG hexamers assembled at the cell surface. *Science*. 2014;343(6176):1260-1263.

38. Loupy A, Lefaucheux C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. *N Engl J Med*. 2013;369(13):1215-1226.

39. Chin C, Chen G, Sequiera F, et al. Clinical usefulness of a novel Ctq assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. *J Heart Lung Transplant*. 2011;30(2):158-163.

40. Courant M, Visentin J, Linares G, et al. The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss. *Nephrol Dial Transplant*. 2018;33(10):1853-1863.

41. Callemeayn J, Ameye H, Lerut E, et al. Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. *Am J Transplant*. 2021;21(7):2413-2423.

42. Kloomjit N, ElTers M, Adam BA, et al. Diffuse C4d staining of peritubular capillaries in renal allograft following bamlanivimab therapy. *Am J Transplant*. 2022;22(1):289-293.

43. Halloran PF, Bohmig GA, Bromberg JS, et al. Discovering novel injury features in kidney transplant biopsies associated with TCMR and donor aging. *Am J Transplant*. 2021;21(5):1725-1739.

44. Kreepala C, Famulski KS, Halloran PF. Fundamental concepts regarding graft injury and regeneration: Tissue injury, tissue quality and recipient factors. In: Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Pearson TC, Webber SA, eds. *Textbook of organ transplantation*. 1st ed. John Wiley & Sons, Ltd.; 2014:99-118.

45. Crespo M, Llinas-Mallol L, Redondo-Pachon D, et al. Non-HLA antibodies and epitope mismatches in kidney transplant recipients with histological antibody-mediated rejection. *Front Immunol*. 2021;12:703457.

46. Jackson KR, Segev DL. Rethinking incompatibility in kidney transplantation. *Am J Transplant*. 2021;22:1031-1036.

47. Jackson AM, Delville M, Lamarthee B, Anglicheau D. Sensitization to endothelial cell antigens: unraveling the cause or effect paradox. *Hum Immunol*. 2019;80(8):614-620.

48. Delville M, Lamarthee B, Pagie S, et al. Early acute microvascular kidney transplant rejection in the absence of anti-HLA antibodies is associated with preformed IgG antibodies against diverse glomerular endothelial cell antigens. *J Am Soc Nephrol*. 2019;30(4):692-709.

49. Soroah BM, Ismail G, Leca N, et al. Angiotensin II type 1 receptor antibodies in kidney transplantation: an evidence-based comprehensive review. *Transplant Rev (Orlando)*. 2020;34(4):100573.

50. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. *Am J Transplant*. 2013;13(4):971-983.

51. Halloran PF, Pereira AB, Chang J, et al. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). *Am J Transplant*. 2013;13(11):2865-2874.

52. Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a fc receptors. *Am J Transplant*. 2015;15(5):1336-1348.

53. Zhang Y, Boesen CC, Radaev S, et al. Crystal structure of the extracellular domain of a human fc gamma RII. *Immunity*. 2000;13(3):387-395.

54. Jordan SC, Ammerman N, Vo A. Implications of fc neonatal receptor (FcRn) manipulations for transplant immunotherapeutics. *Transplantation*. 2020;104(1):17-23.

55. Kessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanilizumab reduces human serum IgG concentration: a randomized phase 1 study. *Sci Transl Med*. 2017;9(414):eaan1208.

56. Bohmig GA, Durr M, Jilma B, et al. Three-month results of a phase 2 trial evaluating Clazakizumab in late antibody-mediated rejection - early impact of Interleukin-6 blockade on donor-specific antibody levels, rejection morphology and gene expression. *Am J Transplant*. 2020;20(3S):404.

57. Choi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-Interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. *Am J Transplant*. 2017;17(9):2381-2389.

58. Doberer K, Klager J, Gualdoni GA, et al. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. *Transplantation*. 2021;105(2):451-457.

59. Eskandary F, Jilma B, Muhlacher J, et al. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial. *Am J Transplant*. 2018;18(4):916-926.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Halloran PF, Madill-Thomsen KS, Pon S, et al. Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes. *Am J Transplant*. 2022;22:1976-1991. doi: [10.1111/ajt.17092](https://doi.org/10.1111/ajt.17092)